Keywords: UK, NICE, Final guidance, Tasigna, Glivec, Sprycel, Victelis, Incivo, Novartis, Bristol-Myers, Merck & Co. Janssen, Johnson & Johnson

UK NICE issues final guidance for Tasigna, Glivec, Sprycel, Victrelis and Incivo

Article | 25 April 2012

Print This

In final guidance issued this morning, UK drugs watchdog the National Institute for Health and Clinical Excellence ( NICE) has recommended ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in